Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Spruce Biosciences, Inc. (NASDAQ: SPRB) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.
Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $1.50 price target on the stock, down previously from $2.00.
Spruce Biosciences, Inc. (NASDAQ: SPRB) had its "market perform" rating re-affirmed by analysts at JMP Securities.